Shares of 89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company surged in morning trading on Wednesday after announcing positive topline data from the Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In this study, patients dosed with 44mg every two weeks and 30mg weekly met both the primary histology endpoints with high statistical significance. Considering this positive data, pegozafermin will now advance to a Phase 3 trial.
Analysts are bullish about ETNB stock with a unanimous six Buys.